Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?